Drug exclusivity: map approval evidence to revenue exposure
A drug patent or exclusivity date is useful only when it is linked to the right product, market and revenue stream. Build a product-level map before describing a “patent cliff.” One date does not establish when a competitor will launch, how substitution will occur or how quickly revenue could change.
Begin with the product identity
FDA Orange Book data identify approved drug products and contain patent and exclusivity information, including application and product identifiers. This is US regulatory evidence for products within that database’s scope. It is not a worldwide patent register, a legal opinion on enforceability or evidence that a listed competitor is commercially shipping.
Match active ingredient, strength, dosage form, application number and product number. A brand can cover several formulations and territories. Do not assign all brand revenue to the earliest date found for one formulation, and do not use the Orange Book as the appropriate database for every biologic.
Hypothetical revenue mapping
Assume fictional Brand Elm generates 600 million in annual revenue: 300 from US immediate-release tablets, 100 from US extended-release tablets and 200 from other markets. In this invented example, the immediate-release product has a relevant exclusivity milestone in Year 1; the extended-release product has a separate milestone in Year 3.
| Product exposure worksheet | Revenue | Evidence needed |
|---|---|---|
| US immediate-release tablets | 300 | Exact application and product identity |
| US extended-release tablets | 100 | Separate patents and exclusivity |
| Other-market sales | 200 | Applicable local regulatory evidence |
| Total brand sales | 600 | Reconcile with company disclosure |
The directly mapped Year 1 revenue population is 300, or 50% of brand revenue. That is an exposure scope, not a forecast of revenue loss. Assuming an immediate 600 decline would combine unmatched products and jurisdictions. Even a scenario applied to the mapped 300 needs separate assumptions about entry timing, pricing and retained volume.
Separate four milestones
Track patent expiry, regulatory exclusivity, competitor approval and commercial launch in different columns. Patent and exclusivity protections can overlap without being identical. Approval indicates a regulatory status; it does not establish inventory, reimbursement, distribution or a launch date. Litigation and settlements require their own primary evidence and should not be inferred from a database date.
Therapeutic-equivalence information also has a defined regulatory role. Do not interpret a similar ingredient name as proof that products are substitutable in every setting. The exact product and jurisdiction determine what additional regulatory or dispensing evidence is relevant.
Test a bounded operating scenario
For the mapped immediate-release population, build an illustrative matrix of retained units and net price rather than a single all-or-nothing assumption. If units retained are 80% and net price is 70% of the starting level, the modeled revenue is 300 × 0.8 × 0.7 = 168. Both percentages are editorial assumptions, not empirical estimates or probabilities.
Keep gross sales separate from rebates and other deductions when the issuer provides net revenue. A competitor’s list price does not mechanically determine the incumbent’s realized price. Supply reliability and channel inventory can also affect the initial observation period.
The next review should verify each milestone against the precise product record and issuer disclosure, then update only the mapped revenue population. This is a research scope exercise, not legal or medical guidance. It cannot establish the validity of patents, the clinical merits of treatments or the value of a pharmaceutical security.
FAQ
Does expiry prove immediate generic competition?
No. Approval, launch, supply and other legal or commercial conditions require separate evidence. Keep the stages distinct.
Can one brand-level date cover all countries?
No. Product rights and regulatory status vary by jurisdiction and formulation. Map the revenue before assigning dates.